Ifidancitinib

• CAT Number: I029205
• CAS Number: 1236667-40-5
• Molecular Formula: C32H33N5O10
• Molecular Weight: 647.64
• Purity: 98%
• Synonyms: Ifidancitinib; ifidancitinibum
• Target: Stem Cell/Wnt
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one
• InChI: InChI=1S/C20H18FN5O3/c1-10-6-13(8-16(28-3)17(10)21)24-19-22-9-11(2)18(26-19)23-12-4-5-15-14(7-12)25-20(27)29-15/h4-9H,1-3H3,(H,25,27)(H2,22,23,24,26)
• InChIKey: OYFMQDVLFYKOPZ-UHFFFAOYSA-N
• SMILES: CC1=CC(=CC(=C1F)OC)NC2=NC=C(C(=N2)NC3=CC4=C(C=C3)OC(=O)N4)C

Ifidancitinib（Cat No.:I029205）is a novel, oral Janus kinase (JAK) inhibitor under investigation for its potential therapeutic applications, primarily in autoimmune and inflammatory conditions. By selectively inhibiting specific JAK enzymes, it modulates the immune system and reduces inflammation, which is beneficial for treating diseases like rheumatoid arthritis, psoriasis, and inflammatory bowel disease (IBD). Ifidancitinib aims to offer a targeted approach with fewer side effects compared to traditional immunosuppressants. Clinical trials are ongoing to evaluate its safety, efficacy, and optimal dosing, and it shows promise in improving symptoms of chronic inflammatory disorders.